TABLE 1.
The relationship between TGFβ2 expression and clinicopathological factors in HMUCH (GSE184336) and TCGA-STAD database.
| Clinical Features | Total | TGFβ2 Expression (HMUCH) | p-Value | Total | TGFβ2 Expression (STAD) | p-Value | ||
|---|---|---|---|---|---|---|---|---|
| Low (%) | High (%) | Low (%) | High (%) | |||||
| Age | 0.948 | 0.864 | ||||||
| <60 | 114 | 57 (49.1) | 57 (49.6) | 105 | 56 (29.8) | 56 (30.6) | ||
| ≥60 | 117 | 59 (50.9) | 58 (50.4) | 236 | 132 (70.2) | 127 (69.4) | ||
| Gender | 0.462 | 0.859 | ||||||
| Female | 83 | 39 (33.6%) | 44 (38.3%) | 122 | 68 (36.2) | 66 (35.3) | ||
| Male | 148 | 77 (66.4%) | 71 (61.7%) | 222 | 120 (63.8) | 121 (64.7) | ||
| TNM stage | 0.708 | 0.453 | ||||||
| Ⅰ | 36 | 20 (17.2) | 16 (13.9) | 53 | 32 (17.5) | 21 (11.9) | ||
| Ⅱ | 49 | 27 (23.3) | 22 (19.1) | 112 | 58 (31.7) | 54 (30.7) | ||
| Ⅲ | 129 | 61 (52.6) | 68 (59.1) | 154 | 74 (40.4) | 80 (45.5) | ||
| Ⅳ | 17 | 8 (6.9) | 9 (7.8) | 40 | 19 (10.4) | 21 (11.9) | ||
| T stage | 0.217 | 0.176 | ||||||
| T1 | 21 | 11 (9.5) | 10 (8.7) | 19 | 14 (7.4) | 5 (2.8) | ||
| T2 | 25 | 17 (14.7) | 8 (7) | 80 | 41 (21.8) | 39 (21.8) | ||
| T3 | 142 | 70 (60.3) | 72 (62.6) | 168 | 87 (46.3) | 81 (45.2) | ||
| T4 | 43 | 18 (15.5) | 25 (21.7) | 100 | 46 (24.5) | 54 (30.2) | ||
| N stage | 0.241 | 0.494 | ||||||
| N0 | 65 | 33 (28.4) | 32 (27.8) | 111 | 63 (34.6) | 48 (27.3) | ||
| N1 | 29 | 19 (16.4) | 10 (8.7) | 97 | 46 (25.3) | 51 (29.0) | ||
| N2 | 44 | 23 (19.8) | 21 (18.3) | 76 | 36 (19.8) | 40 (22.7) | ||
| N3 | 93 | 41 (35.3) | 52 (45.2) | 74 | 37 (20.3) | 37 (21) | ||
| Histologic Grade | 0.606 | 0.003 | ||||||
| G1 | 4 | 3 (2.6) | 1 (0.9) | 10 | 7 (3.8) | 3 (1.7) | ||
| G2 | 92 | 46 (39.6) | 46 (40) | 138 | 84 (45.2) | 54 (29.8) | ||
| G3 | 135 | 67 (57.8) | 68 (59.1) | 219 | 95 (51.0) | 124 (68.5) | ||
Bold values indicate p-value < 0.05.